Jagsonpal Pharmaceuticals considers its 1st-ever buyback
Jagsonpal Pharmaceuticals is thinking about buying back its own shares for the very first time, with a board meeting set for March 12, 2026.
This move is often interpreted as management expressing confidence in the company's future, and may indicate management believes the stock is undervalued.
Strong sales and profit margins
Jagsonpal's not just making bold moves: it's backing it up with numbers.
Sales jumped nearly 29% in 2025 to ₹2,687 million, and profits hit ₹554 million with strong margins over 20%.
Even after buying another company for ₹950 million (all from its own funds), it still has plenty of cash left.
The company is also focusing on unique products (especially in gynecology) and plans to keep launching new ones every year.
For investors or anyone curious about smart business plays, this is a sign of confidence and growth worth watching.
(Note: the cited sales/profit figures and their attribution to 2025 are not confirmed by the source; please verify with a primary source.)